Pubdate: Mon, 15 Nov 2004
Source: Lexington Herald-Leader (KY)
Copyright: 2004 Lexington Herald-Leader
Contact:  http://www.kentucky.com/mld/heraldleader/
Details: http://www.mapinc.org/media/240
Author: Malcolm Ritter, Associated Press
Bookmark: http://www.mapinc.org/mmj.htm (Cannabis - Medicinal)
Bookmark: http://www.mapinc.org/coke.htm (Cocaine)

NEW DRUG COULD HELP FIGHT ADDICTION

Today's topic: Rimonabant

NEW YORK - A pill that helps you lose weight and quit smoking? That was 
amazing enough to capture headlines last week. But scientists say the 
experimental drug might be even more versatile, providing a new tool to 
help people stop abusing drugs and alcohol, too.

It's called rimonabant, or Acomplia, and last week, researchers reported it 
could help people not only lose weight but keep it off for two years.

That burnished the drug's reputation after two studies in March suggested 
it could fight both obesity and smoking, two of humanity's biggest killers.

The French pharmaceutical firm Sanofi-Aventis plans to seek federal 
approval for rimonabant next year.

The drug's benefits may go beyond just smokers and obese people, 
researchers say.

"I think it's going to have a big impact on the treatment of addiction," 
said Dr. Charles O'Brien, an addiction expert at the University of 
Pennsylvania and the Philadelphia Veterans Affairs Medical Center.

Animal studies suggest rimonabant can block the effects of marijuana and 
fight relapse in alcohol and cocaine abuse, he said. Once it is approved 
for treating obesity or smoking, "we'll be free to study it in these other 
areas, and I'll try to get my hands on it as quickly as possible," O'Brien 
said.

Many others share his enthusiasm.

The National Institute on Alcohol Abuse and Alcoholism is interested in 
seeing whether rimonabant can help treat heavy drinkers, said Dr. George 
Kunos of the institute. No human test results for rimonabant in alcohol 
abuse have yet been published, he said.

But researchers at the National Institute on Drug Abuse reported in 2001 
that a single dose of the drug could block the effects of smoked marijuana 
in people, not just animals. That suggests the drug could be useful in 
treating marijuana dependence, said Marilyn Huestis, principal investigator 
of the study. The institute is now pursuing follow-up research, said 
Huestis, acting chief for chemistry and drug metabolism research at NIDA.

Rimonabant's versatility traces back to its effects on the brain's reward 
system, circuitry that tells you to keep on doing something. Basically, it 
appears to help break the connection between an activity like smoking and 
the rewarding feeling it causes in the brain.

The body has its own marijuana-like substances called endocannabinoids, and 
they activate certain brain cells that in turn can lead to stimulation of 
the brain's reward system. Pleasurable things like drinking alcohol are 
thought to activate a feeling of reward by acting through the 
endocannabinoid system.

"We think that the (endocannabinoid) system is overactivated by chronic 
smoking, or perhaps even excessive overeating," said Dr. Robert Anthenelli 
of the University of Cincinnati College of Medicine and the Cincinnati 
Veterans Affairs Medical Center.

Rimonabant blocks the effect of the natural endocannabinoids by keeping 
them from latching onto the brain cells they normally stimulate, he said. 
In smokers, for example, that seems to restore the natural balance of the 
brain reward circuitry, he said.
- ---
MAP posted-by: Jo-D